Literature DB >> 3258319

Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.

S Okusawa1, J A Gelfand, T Ikejima, R J Connolly, C A Dinarello.   

Abstract

In addition to activating T and B lymphocytes, interleukin 1 (IL-1) induces several hematologic and metabolic changes typical of host responses to infection and injury. We now report a new biological property, namely, the induction of hypotension. Rabbits given a single intravenous injection of recombinant human IL-1-beta (5 micrograms/kg) rapidly developed decreased systemic arterial pressure, which reached the lowest levels after 50-60 min and slowly returned to pre-IL-1 values after 3 h. Associated with the hypotension, systemic vascular resistance and central venous pressure fell, while cardiac output and heart rate increased. These responses were prevented by ibuprofen given 15 min before the IL-1. A bolus injection of IL-1 followed by a 2-h infusion sustained the hypotension and was associated with leukopenia and thrombocytopenia. Ibuprofen given at the mid-point of the infusion reversed the changes in all hemodynamic parameters, but had no effect on the leukopenia or thrombocytopenia. Tumor necrosis factor (TNF) also induced a shock-like state in rabbits. When the dose of IL-1 or TNF was reduced to 1 microgram/kg, no hemodynamic changes were observed; however, the combination of these low doses of both cytokines resulted in a profound shock-like state including histological evidence of severe pulmonary edema and hemorrhage. Pretreatment with ibuprofen prevented the hemodynamic, leukocyte, and platelet changes induced by the low-dose cytokine combination, and ameliorated the pulmonary tissue damage. These results demonstrate that IL-1, like TNF, possesses the ability to induce hemodynamic and hematological changes typical of septic shock, and that the combination of IL-1 and TNF is more potent than either agent alone. These effects seem to require cyclooxygenase products, and suggest that intravenous cyclooxygenase inhibitors may be of therapeutic value in patients with IL-1/TNF-mediated shock.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258319      PMCID: PMC329645          DOI: 10.1172/JCI113431

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  In vitro enhanced thromboxane B2 release by polymorphonuclear leukocytes and macrophages after treatment with human recombinant interleukin 1.

Authors:  P Conti; M G Cifone; E Alesse; M Reale; C Fieschi; C A Dinarello
Journal:  Prostaglandins       Date:  1986-07

2.  Protective effects of ibuprofen and methylprednisolone on chemotactic factor-induced transcutaneous hypoxia.

Authors:  E G Maderazo; S P Breaux; C L Woronick
Journal:  J Pharmacol Exp Ther       Date:  1986-08       Impact factor: 4.030

3.  Biological effects of bacterial endotoxins in man.

Authors:  S M Wolff
Journal:  J Infect Dis       Date:  1973-07       Impact factor: 5.226

4.  The detection of endotoxin by in vitro production of endogenous pyrogen: comparison with limulus amebocyte lysate gelation.

Authors:  G W Duff; E Atkins
Journal:  J Immunol Methods       Date:  1982-08-13       Impact factor: 2.303

5.  Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells.

Authors:  P Libby; J M Ordovas; K R Auger; A H Robbins; L K Birinyi; C A Dinarello
Journal:  Am J Pathol       Date:  1986-08       Impact factor: 4.307

6.  Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.

Authors:  P B Chapman; T J Lester; E S Casper; J L Gabrilove; G Y Wong; S J Kempin; P J Gold; S Welt; R S Warren; H F Starnes
Journal:  J Clin Oncol       Date:  1987-12       Impact factor: 44.544

7.  Implications for thromboxane A2 in the pathogenesis of endotoxic shock.

Authors:  W C Wise; J A Cook; P V Halushka
Journal:  Adv Shock Res       Date:  1981

8.  Ibuprofen in canine endotoxin shock.

Authors:  E R Jacobs; M E Soulsby; R C Bone; F J Wilson; F C Hiller
Journal:  J Clin Invest       Date:  1982-09       Impact factor: 14.808

9.  Thromboxane, prostacyclin, and the hemodynamic effects of graded bacteremic shock.

Authors:  G J Slotman; J V Quinn; K W Burchard; D S Gann
Journal:  Circ Shock       Date:  1985

10.  Prostaglandin E2 and fever: a continuing debate.

Authors:  F Coceani; I Bishai; J Lees; S Sirko
Journal:  Yale J Biol Med       Date:  1986 Mar-Apr
View more
  203 in total

Review 1.  Bloodstream infections: epidemiology, pathophysiology and therapeutic perspectives.

Authors:  R Salomão; O Rigato; A C Pignatari; M A Freudenberg; C Galanos
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 3.553

2.  Hematopoietic stem-progenitor cells restore immunoreactivity and improve survival in late sepsis.

Authors:  Laura Brudecki; Donald A Ferguson; Deling Yin; Gene D Lesage; Charles E McCall; Mohamed El Gazzar
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

3.  Adjunctive Therapies for Sepsis and Septic Shock.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

4.  The pulmonary inflammatory response to experimental fecal peritonitis: relative roles of tumor necrosis factor-alpha and endotoxin.

Authors:  M A Mercer-Jones; M Heinzelmann; J C Peyton; D J Wickel; M Cook; W G Cheadle
Journal:  Inflammation       Date:  1997-08       Impact factor: 4.092

Review 5.  [Continuous dialysis and hemofiltration. More than a kidney replacement method?].

Authors:  M Girndt; H Köhler
Journal:  Anaesthesist       Date:  2003-12       Impact factor: 1.041

6.  Recombinant interleukin-1 alpha and recombinant tumor necrosis factor alpha synergize in vivo to induce early endotoxin tolerance and associated hematopoietic changes.

Authors:  S N Vogel; E N Kaufman; M D Tate; R Neta
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

7.  Provocation of pulmonary vascular endothelial injury in rabbits by human recombinant interleukin-1 beta.

Authors:  S E Goldblum; K Yoneda; D A Cohen; C J McClain
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

8.  The effect of adrenalectomy on interleukin-1 release in vitro and in vivo.

Authors:  M Perretti; C Becherucci; G Scapigliati; L Parente
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

Review 9.  Interleukin-1 and the effects of cyclooxygenase inhibitors on its biological activities.

Authors:  C A Dinarello
Journal:  Bull N Y Acad Med       Date:  1989-01

10.  Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury.

Authors:  A Seekamp; J S Warren; D G Remick; G O Till; P A Ward
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.